Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Cerebrolysin was well tolerated and demonstrated improved cognition in Alzheimer patients
March 24th, 2006
Cerebrolysin was well tolerated and demonstrated improved cognition in Alzheimer patients. According to a study from Spain, "Cerebrolysin (Cere) is a compound with neurotrophic activity shown to be effective in Alzheimer's disease in earlier trials. The efficacy and safety of three dosages of Cere were investigated in this randomized, double-blind, placebo-controlled, study." X.A. Alvarez and colleagues from EuroEspes Biomedical Research Center wrote, "Two hundred and seventy-nine patients were enrolled (69 Cere 10 ml; 70 Cere 30 ml; 71 Cere 60 ml and 69 placebo). Patients received iv infusions of 10, 30, 60 ml Cere or placebo 5 days/week for the...
Source: Drug Week (2006-03-24)
|
